Creative medical technology holdings announces key milestones regarding immcelz® platform development

Independent studies validate enhanced clinical grade cell production for patient use in multiple indications at a fraction of current industry cost phoenix , march 21, 2023 /prnewswire/ -- creative medical technology holdings, inc. (nasdaq: celz), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced third party validation regarding several aspects of its  immcelz® (celz-100) development program, the company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders.   these independent studies demonstrated:  a 400% increase in the clinical grade cell production yield at the same cost profile as the company's first generation immcelz line; functional suppression of effector t cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional t regulatory cells; and the ability to verify repeated potency of the final immcelz®(celz-100) product.
CELZ Ratings Summary
CELZ Quant Ranking